Rezulin benefit/risk ratio is supported by FDA
Labeling revisions in June "have been effective in reducing the rate of reported adverse liver events" for Rezulin, Warner-Lambert says. No deaths or transplants have been reported since June, company claims. Firm declares that reports of a Rezulin withdrawal are untrue. Warner-Lambert said it has had "productive meetings with the FDA regarding Rezulin, which are part of the agency's ongoing monitoring of this therapy for type 2 diabetes," and the agency has stated that "at this time, the FDA continues to consider the benefit versus risk profile to be favorable when used according to the approved labeling"
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth